In the amyloid hypothesis of Alzheimer’s disease (AD), the dysregulation of amyloid-β protein (Aβ) production and clearance leads to amyloid deposits, tau tangles, neuronal loss, and cognitive dysfunction. Thus far, therapies targeting the enzymes responsible for Aβ production have been found ineffective or having significant side effects.
Objective:
To test whether a γ-secretase modulator, BPN-15606, is an effective disease-modifying or preventative treatment in the PSAPP mouse model of AD.
Methods:
We treated pre-plaque (3-month-old) and post-plaque (6-month-old) PSAPP AD transgenic mice for 3 months and examined behavioral, biochemical, and pathological end points.
Results:
BPN-15606 attenuated cognitive impairment and reduced amyloid plaque load, microgliosis, and astrogliosis associated with the AD phenotype of PSAPP mice when administered to pre-plaque (3-month-old) but was ineffective when administered to post-plaque (6-month-old) mice. No treatment-related toxicity was observed.
Conclusion:
BPN-15606 appears efficacious when administered prior to significant pathology.
WagnerSL, TanziRE, MobleyWC, GalaskoD (2012) Potential use of gamma-secretase modulators in the treatment of Alzheimer disease. Arch Neurol69, 1255–1258.
6.
Serrano-PozoA, FroschMP, MasliahE, HymanBT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med1, a006189.
7.
BorcheltDR, ThinakaranG, EckmanCB, LeeMK, DavenportF, RatovitskyT, PradaCM, KimG, SeekinsS, YagerD, SluntHH, WangR, SeegerM, LeveyAI, GandySE, CopelandNG, JenkinsNA, PriceDL, YounkinSG, SisodiaSS (1996) Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron17, 1005–1013.
8.
ScheunerD, EckmanC, JensenM, SongX, CitronM, SuzukiN, BirdTD, HardyJ, HuttonM, KukullW, LarsonE, Levy-LahadE, ViitanenM, PeskindE, PoorkajP, SchellenbergG, TanziR, WascoW, LannfeltL, SelkoeD, YounkinS (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med2, 864–870.
9.
CitronM, EckmanCB, DiehlTS, CorcoranC, OstaszewskiBL, XiaW, LevesqueG, St George HyslopP, YounkinSG, SelkoeDJ (1998) Additive effects of PS1 and APP mutations on secretion of the 42-residue amyloid beta-protein. Neurobiol Dis5, 107–116.
10.
AhnK, SheltonCC, TianY, ZhangX, GilchristML, SisodiaSS, LiYM (2010) Activation and intrinsic gamma-secretase activity of presenilin 1. Proc Natl Acad Sci U S A107, 21435–21440.
DoodyRS, RamanR, FarlowM, IwatsuboT, VellasB, JoffeS, KieburtzK, HeF, SunX, ThomasRG, AisenPS, Alzheimer’s Disease Cooperative Study Steering Committee, SiemersE, SethuramanG, MohsR, Semagacestat Study Group (2013) A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med369, 341–350.
CoricV, van DyckCH, SallowayS, AndreasenN, BrodyM, RichterRW, SoininenH, TheinS, ShiovitzT, PilcherG, ColbyS, RollinL, DockensR, PachaiC, PorteliusE, AndreassonU, BlennowK, SoaresH, AlbrightC, FeldmanHH, BermanRM (2012) Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol69, 1430–1440.
TakasugiN, TomitaT, HayashiI, TsuruokaM, NiimuraM, TakahashiY, ThinakaranG, IwatsuboT (2003) The role of presenilin cofactors in the gamma-secretase complex. Nature422, 438–441.
18.
SteinerH, WinklerE, HaassC (2008) Chemical cross-linking provides a model of the gamma-secretase complex subunit architecture and evidence for close proximity of the C-terminal fragment of presenilin with APH-1. J Biol Chem283, 34677–34686.
19.
KaetherC, CapellA, EdbauerD, WinklerE, NovakB, SteinerH, HaassC (2004) The presenilin C-terminus is required for ER-retention, nicastrin-binding and γ-secretase activity. EMBO J23, 4738–4748.
20.
LiuQ, WaltzS, WoodruffG, OuyangJ, IsraelMA, HerreraC, SarsozaF, TanziRE, KooEH, RingmanJM, GoldsteinLSB, WagnerSL, YuanSH (2014) Effect of potent γ-secretase modulator in human neurons derived from multiple presenilin 1–induced pluripotent stem cell mutant carriers. JAMA Neurol71, 1481–1489.
21.
BerezovskaO, JackC, McLeanP, AsterJC, HicksC, XiaW, WolfeMS, KimberlyWT, WeinmasterG, SelkoeDJ, HymanBT (2000) Aspartate mutations in presenilin and gamma-secretase inhibitors both impair notch1 proteolysis and nuclear translocation with relative preservation of notch1 signaling. J Neurochem75, 583–593.
22.
LessardCB, WagnerSL, KooEH (2010) And four equals one: Presenilin takes the gamma-secretase role by itself. Proc Natl Acad Sci U S A107, 21236–21237.
23.
BorcheltDR, RatovitskiT, van LareJ, LeeMK, GonzalesV, JenkinsNA, CopelandNG, PriceDL, SisodiaSS (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron19, 939–945.
24.
TsaiJ, GrutzendlerJ, DuffK, GanWB (2004) Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci7, 1181–1183.
25.
RuttenBP, Van der KolkNM, SchaferS, van ZandvoortMA, BayerTA, SteinbuschHW, SchmitzC (2005) Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice. Am J Pathol167, 161–173.
26.
ZhangC, KuoCC, MoghadamSH, MonteL, CampbellSN, RiceKC, SawchenkoPE, MasliahE, RissmanRA (2016) Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer’s disease. Alzheimers Dement12, 527–537.
27.
MatsuokaY, PiccianoM, MalesterB, LaFrancoisJ, ZehrC, DaeschnerJM, OlschowkaJA, FonsecaMI, O’BanionMK, TennerAJ, LemereCA, DuffK (2001) Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer’s disease. Am J Pathol158, 1345–1354.
28.
WagnerSL MW, TanziRE, JohnsonG, BuckleRN, MayhewNJ, HerrRJ, RynearsonKD (2016) Potent gamma-secretase modulators. Regents of the University of California and General Hospital Corporation. International Patent Classification: WO2016/070107.
29.
KounnasMZ, DanksAM, ChengS, TyreeC, AckermanE, ZhangX, AhnK, NguyenP, ComerD, MaoL, YuC, PleynetD, DigregorioPJ, VelicelebiG, StaudermanKA, ComerWT, MobleyWC, LiYM, SisodiaSS, TanziRE, WagnerSL (2010) Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer’s disease. Neuron67, 769–780.
30.
SelkoeDJ (1994) Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer’s disease. Annu Rev Cell Biol10, 373–403.
31.
SchwabC, KlegerisA, McGeerPL (2010) Inflammation in transgenic mouse models of neurodegenerative disorders. Biochim Biophys Acta1802, 889–902.
32.
ItoD, ImaiY, OhsawaK, NakajimaK, FukuuchiY, KohsakaS (1998) Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res57, 1–9.
33.
EngLF, GhirnikarRS (1994) GFAP and astrogliosis. Brain Pathol4, 229–237.
34.
SofroniewMV (2014) Astrogliosis. Cold Spring Harb Perspect Biol7, a020420.
35.
McGowanE, SandersS, IwatsuboT, TakeuchiA, SaidoT, ZehrC, YuX, UljonS, WangR, MannD, DicksonD, DuffK (1999) Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis6, 231–244.
36.
BignamiA, EngLF, DahlD, UyedaCT (1972) Localization of the glial fibrillary acidic protein in astrocytes by immunofluorescence. Brain Res43, 429–435.
TanziRE, BertramL (2005) Twenty years of the Alzheimer’s disease amyloid hypothesis: A genetic perspective. Cell120, 545–555.
39.
D’AndreaMR, ColeGM, ArdMD (2004) The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol Aging25, 675–683.
40.
Serrano-PozoA, MuzikanskyA, Gomez-IslaT, GrowdonJH, BetenskyRA, FroschMP, HymanBT (2013) Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropathol Exp Neurol72, 462–471.
41.
TakeuchiA, IrizarryMC, DuffK, SaidoTC, Hsiao AsheK, HasegawaM, MannDM, HymanBT, IwatsuboT (2000) Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol157, 331–339.
42.
Jurisch-YaksiN, SannerudR, AnnaertW (2013) A fast growing spectrum of biological functions of gamma-secretase in development and disease. Biochim Biophys Acta1828, 2815–2827.
43.
PuzzoD, PriviteraL, FaM, StaniszewskiA, HashimotoG, AzizF, SakuraiM, RibeEM, TroyCM, MerckenM, JungSS, PalmeriA, ArancioO (2011) Endogenous amyloid-beta is necessary for hippocampal synaptic plasticity and memory. Ann Neurol69, 819–830.
44.
EimerWA, Vijaya KumarDK, Navalpur ShanmugamNK, RodriguezAS, MitchellT, WashicoskyKJ, GyorgyB, BreakefieldXO, TanziRE, MoirRD (2018) Alzheimer’s disease-associated beta-amyloid is rapidly seeded by herpesviridae to protect against brain infection. Neuron100, 1527–1532.
45.
GosztylaML, BrothersHM, RobinsonSR (2018) Alzheimer’s amyloid-beta is an antimicrobial peptide: A review of the evidence. J Alzheimers Dis62, 1495–1506.
46.
HenleyD, RaghavanN, SperlingR, AisenP, RamanR, RomanoG (2019) Preliminary results of a trial of atabecestat in preclinical Alzheimer’s disease. N Engl J Med380, 1483–1485.
47.
EganMF, KostJ, VossT, MukaiY, AisenPS, CummingsJL, TariotPN, VellasB, van DyckCH, BoadaM, ZhangY, LiW, FurtekC, MahoneyE, Harper MozleyL, MoY, SurC, MichelsonD (2019) Randomized trial of verubecestat for prodromal Alzheimer’s disease. N Engl J Med380, 1408–1420.
48.
KnopmanDS (2019) Lowering of amyloid-beta by beta-secretase inhibitors - some informative failures. N Engl J Med380, 1476–1478.
